The Centers for Medicare & Medicaid Services (CMS) has recognized the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium as a mandated reference for making coverage decisions on the use of drugs and biologics in cancer care.
The NCCN compendium will be used by CMS for its national coverage determinations and by intermediaries and carriers for their regional determinations. One important application will be guiding decisions about coverage for the use of drugs and biologics in oncology beyond the FDA-approved indication.
The NCCN is an alliance of 21 of the world?s leading cancer centers dedicated to promoting high-quality cancer care; its clinical oncology practice guidelines are used widely by patients, clinicians, and other health care decision makers.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs